X
<

Bristol-Myers Squibb’s Latest Developments and Valuation

PART:
1 2 3 4 5 6 7 8
Part 7
Bristol-Myers Squibb’s Latest Developments and Valuation PART 7 OF 8

Bristol-Myers Squibb’s Immunoscience Products

Immunoscience products

Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.

Bristol-Myers Squibb’s Immunoscience Products

Interested in ABT? Don't miss the next report.

Receive e-mail alerts for new research on ABT

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows revenues from Orencia over the last few quarters.

Orencia

Orencia is a drug that reduces the pain in moderate-to-severe rheumatoid arthritis and also helps to reduce further joint damage. Orencia reported 10% growth in revenues to $650 million in 2Q17, compared to revenues of $593 million in 2Q16. The growth in revenues was driven by an increase in sales in US as well as international markets.

Orencia reported 12% growth in US sales to $449 million in 2Q17, compared to revenues of $401 million in 2Q16.

Other brands from Bristol-Myers Squibb

The other brands from Bristol-Myers Squibb’s product portfolio include various products that have lost exclusivity in major markets, over-the-counter products, and royalty revenues. Overall, the revenues from other brands fell ~16% to $479 million in 2Q17, compared to $572 million for 2Q16.

Other brands reported a 5% fall in US sales to $92 million in 2Q17, compared to $97 million in 2Q16.

To divest company-specific risks, investors can consider ETFs like the First Trust NASDAQ Pharmaceuticals (FTXH), which invests 4.6% of its portfolio in Bristol-Myers Squibb (BMY). FTXH also invests 8.2% in Pfizer (PFE), 9.1% in Abbott Laboratories (ABT), and 4.1% in Eli Lilly and Co. (LLY).

X

Please select a profession that best describes you: